Rheumatoid Arthritis.

Slides:



Advertisements
Similar presentations
Planning for Biosimilars: Infliximab Professor Ray Fitzpatrick Secondary Care lead Keele University Clinical Director of Pharmacy Royal Wolverhampton NHS.
Advertisements

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs : 2013 update Smolen.
Case-Based Examination of Treatment Options in Type 2 Diabetes Management.
A NEW LOOK AT RA Interactive Hot Topics Series
Upfront Combination Therapy vs Step-Up Approach for PAH:
Rheumatoid arthritis The Lancet
Individualizing Treatment Options in Advanced ER-Positive Breast Cancer.
My Treatment Approach to Rheumatoid Arthritis
Psoriatic Arthritis.
Introduction/Background
Clinical Developments in Inflammatory Arthritis 2017
CDK 4 and 6 Inhibitors in HR-Positive Breast Cancer: A Clinical Update
Updates on Emerging GLP-1 Receptor Agonists
Introduction/Background
Introducing JAK Inhibitors in Rheumatoid Arthritis
Current and Emerging Treatments for IBD
Diagnosing Rheumatoid Arthritis Early
Access to NOAC Therapy:
Part 1: Disease Activity Measures
Biosimilars in RA: A Blessing or a Curse?
SGLT2 Inhibitors in Phase 3 Trials
Expert Insights on Psoriatic Arthritis From Washington, DC
My Treatment Approach to Rheumatoid Arthritis
Novel Small Molecule Therapies in Rheumatoid Arthritis
Comparing Treatment Alternatives in Ankylosing Spondylitis
Surveying the Safety of NOACs in the Real World
Minding the Gap Rheumatoid Arthritis Advances From London 2016
What Is a Biosimilar?. Biosimilar Application in RA Clinical Practice: Current Knowledge and New Data  
Clinical Updates in RA: New Developments and Insights From Washington
Is it Time for a Paradigm Change in HIV Management?
Access to NOAC Therapy:
Is RA Treatment Addressing the Real Needs of Patients?
Next-Gen Psoriasis Therapies:
Rheumatoid Arthritis 2015 Guidelines What's New? What's Different?
Emerging Atopic Dermatitis Treatments:
What’s new in my specialty- Rheumatoid Arthritis
Evolving Treatment Landscape for PsA
Biotherapeutics.
Emerging Frontline Treatments for Patients With Hodgkin Lymphoma
Debating the Issues in Rheumatoid Arthritis with the Experts: Early Treatment and Targets.
When Is Biologic Therapy Appropriate for HS?
Improving Outcomes in Psoriatic Arthritis
Advances in Rheumatoid Arthritis Management
What's New in Therapeutic Options for Moderate to Severe RA?
Advancing Patient Care in RA
Battling the Flu: Latest Advances in the Influenza Treatment Arsenal
Application of Biosimilars in RA IN Clinical Practice: Key Issues and Challenges  
Viewpoints of Practicing Rheumatologists: Case Discussions in RA
Defining Patient-Centered Care: Spotlight on Advanced Non-Small Cell Lung Cancer.
Critical Decision Points in Insomnia
Update on the Management of Atopic Dermatitis
Updates in RA, PsA, and Biosimilars
Improving Effective Basal Insulin Use in Clinical Practice
Patient disposition through 48 weeks in RA-BEYOND
Giant Cell Arteritis.
Peanut Allergy Immunotherapy
AMD Therapy: Where Are We Now and Where Are We Going?
Real-World Evidence.
Nat. Rev. Rheumatol. doi: /nrrheum
Step-down efficacy through week 48: categorical CDAI state DMARD-IR (RA-BEAM, RA-BUILD, RA-BEACON) analysis set. Step-down efficacy through week 48: categorical.
Patient disposition after 2 years of treatment.
Design for the long-term extension study RA-BEYOND from randomisation in the originating studies. Design for the long-term extension study RA-BEYOND from.
Treatment Advances for RA
Patient-level radiographic progression of structural joint damage at year 1 and year 2 by original randomisation. Patient-level radiographic progression.
Disease Activity Cutoffs for ACR-Recommended RA Disease Activity Measure
Biosimilars in Immune-Related Diseases
Meet the JAKs.
What's New in NOACs in AF?.
Psoriatic Arthritis.
You Don't Know JAK in IBD.
Presentation transcript:

Rheumatoid Arthritis

Introduction

Methotrexate Discontinuation and Dose Decreases After Therapy With Tocilizumab

JAK/STAT Pathway: Communication From Transmembrane Receptors to the Nucleus

Currently Available JAK Inhibitors for RA

Early vs Delayed Start of Baricitinib in Patients Naive to MTX Treatment

MTX Withdrawal in Patients Who Achieve LDA With Tofacitinib MR 11 mg QD + MTX

Efficacy and Safety of Peficitinib in Patients Who Had an Inadequate Response to MTX

Efficacy and Safety of Peficitinib in Patients Who Had an Inadequate Response to DMARDs

FINCH1: Efficacy and Safety of Filgotinib in MTX-IR Patients

FINCH3: Efficacy and Safety of Filgotinib in MTX-Naive Patients

FINCH2: Subgroup Analyses

Switching Between Upadacitinib and ADA Following Initial Non-Response

Upadacitinib SELECT Trials: 48-Week Results

Fenebrutinib Compared to PBO and ADA in MTX-IR or TNF-IR Patients

Safety and Efficacy of LY3337641 in Patients With RA: Phase 2 Study

Subcutaneous Administration of Infliximab Biosimilar (CT-P13)

Concluding Remarks

Abbreviations

Abbreviations (cont)